DANVILLE, Calif., May 2, 2017 /PRNewswire/ -- Palo Alto Health Sciences, Inc. (PAHS), developer of the Freespira® treatment for panic attacks and other symptoms of panic disorder, today announced that it has partnered with Silicon Valley TMS, the leading San Francisco Bay Area provider of neuro-psychiatric services, to offer the Freespira Program.
The Freespira Program is a comprehensive and medication-free treatment for patients with panic. The patient, once authorized, is trained by a technician and then takes Freespira home to perform two, 17-minute breathing sessions a day for four weeks. During treatment, the patient is remotely monitored and coached by the PAHS practice coordination team. When the four-week treatment is complete, the patient returns to the Clinic for a follow-up visit.
A recently published multi-center Freespira clinical trial demonstrated that 71% of patients eliminated panic attacks immediately after treatment, and 79% of patients were panic attack free 12 months post-treatment.
Silicon Valley TMS Founder and Chief Medical Officer Dr. Saad A. Shakir comments, "Freespira is an excellent fit with our Clinics because we can now offer patients the most advanced, medication-free and evidence-based treatments for depression, anxiety and panic. It is not uncommon for patients suffering from depression to also suffer from other mental health conditions, including panic attacks and panic disorder."
Dr. Shakir added, "We're happy to provide the most effective care to our patients and community. Freespira provides an innovative approach to treat panic attacks and panic disorder without using medications. This complements the other modalities of treatment that we provide within our multidisciplinary and comprehensive group practice."
Debra Reisenthel, PAHS CEO, agreed, "Freespira offers hope to the many patients with panic attacks and panic disorder who prefer a non-drug approach because of the side effects of medications, or who have not tried or have not responded to talk therapies. We are excited to partner with Dr. Shakir and Silicon Valley TMS to offer the Freespira Program to help even more patients in the San Francisco Bay Area."
Freespira is an FDA-cleared, non-invasive, medication-free, four-week at-home treatment for panic attacks and other panic symptoms. Treatment is authorized and completed under the supervision of a licensed healthcare provider. Freespira is clinically proven to reduce or eliminate panic attacks and other symptoms of panic disorder, a mental health condition in which debilitating anxiety leads to life-altering avoidance behaviors. Individuals with panic chronically hyperventilate, even when not experiencing a panic attack. This abnormal breathing pattern has been shown to exacerbate attacks. Freespira works by training the patient to stabilize respiration rate and exhaled carbon dioxide levels, which reduces or eliminates panic attacks.
About Silicon Valley TMS
Silicon Valley TMS provides patients in the Bay Area with the latest in evidence-based mental health treatments including Transcranial Magnetic Stimulation (r-TMS) such as Neurostar® TMS Therapy system and Brainsway Deep TMS Therapy. TMS is one of the most technologically advanced depression treatments available. This non-invasive, FDA cleared (2008), outpatient therapy has helped thousands of patients with depression and other neuro-psychiatric conditions, who have not received adequate results from medications and psychotherapies. Silicon Valley TMS was founded by Saad A. Shakir, MD, and associates (Integrated Clinical Neurosciences) as part of their private practice group in December 2010. http://www.siliconvalleytms.com/
About Palo Alto Health Sciences, Inc.
Palo Alto Health Sciences, Inc. is a privately held digital therapeutic company at the forefront of revolutionizing behavioral healthcare with evidence-based, non-invasive, drug-free solutions. Their first product, Freespira, is an FDA-cleared treatment for individuals suffering from panic disorder, panic attacks and other symptoms of panic. In the United States, over 6.7 million adults annually suffer from panic disorder; panic attacks affect a total of 27 million adults in the U.S. every year and are a common component of other anxiety disorders.
Freespira is commercially available throughout the U.S. and is currently being evaluated by Anthem and Highmark Health in regional Quality Improvement Programs to assess Freespira's impact in reducing the elevated medical costs of treating patients with panic disorder. To learn more, visit http://www.freespira.com or contact email@example.com.
Michele Kong (800) 735- 8995
SOURCE Palo Alto Health Sciences